Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Education Method of Fluterol Inhaler for Asthma Control
NCT03110874Phase 4Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Sep 2016
01
Overview
Phase 4, randomised, open-label trial in asthma (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Percent change in Forced expiratory volume 1 sec (% prediction) at 12 weeks. Started Oct 2015; status: completed.
02
Conditions
asthma
Beyond the preview
Go deeper on NCT03110874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110874.